Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Mallat, ZiadSteg, Phillippe Gabriel
Benessiano, Joelle
Tanguy, Marie-Laure
Fox, Keith A. A.
Collet, Jean-Philippe
Dabbous, Omar H.
Henry, Patrick
Carruthers, Kathryn F.
Dauphin, Anne
Arguelles, Carla Sibella
Masliah, Joelle
Hugel, Benedicte
Montalescot, Gilles
Freyssinet, Jean-Marie
Asselain, Bernard
Tedgui, Alain
UMass Chan Affiliations
Center for Outcomes ResearchDocument Type
Journal ArticlePublication Date
2005-10-04Keywords
Acute DiseaseAngina, Unstable
C-Reactive Protein
Female
Humans
Interleukin-18
Male
Middle Aged
Myocardial Infarction
Phospholipases A
Phospholipases A2
Prognosis
Recurrence
Severity of Illness Index
Health Services Research
Metadata
Show full item recordAbstract
OBJECTIVES: The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS). BACKGROUND: The plasma level of type IIA sPLA2 is a risk factor for coronary artery disease (CAD) and is associated with adverse outcomes in patients with stable CAD. The prognostic impact of sPLA2 in patients with ACS is unknown. METHODS: Secretory phospholipase A2 antigen levels and activity were measured in plasma samples of 446 patients with ACS, obtained at the time of enrollment. RESULTS: Baseline sPLA2 activity was associated with the risk of death and myocardial infarction (MI). The unadjusted rate of death and MI increased in a stepwise fashion with increasing tertiles of sPLA2 activity (p < 0.0001). The association remained significant in the subgroup of patients who had MI with ST-segment elevation (p = 0.014) and the subgroup of patients who had unstable angina or non-ST-segment elevation MI (p < 0.002). After adjustment for clinical and biological variables, the hazard ratios for the combined end point of death or MI in the third tertile of sPLA2 compared with the first and second tertiles was 3.08 (95% confidence interval, 1.37 to 6.91, p = 0.006). CONCLUSIONS: A single measurement of plasma sPLA2 activity at the time of enrollment provides strong independent information to predict recurrent events in patients with ACS.Source
J Am Coll Cardiol. 2005 Oct 4;46(7):1249-57. Link to article on publisher's siteDOI
10.1016/j.jacc.2005.06.056Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27252PubMed ID
16198839Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jacc.2005.06.056